Ocugen
OCGN

$1.11

2.63%

Market Cap: $320M

About: Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

Employees: 84

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,728 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

257% more call options, than puts

Call options by funds: $1.85M | Put options by funds: $518K

100% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 12

91% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 23

90% more capital invested

Capital invested by funds: $54.9M [Q1] → $104M (+$49.5M) [Q2]

26% more funds holding

Funds holding: 80 [Q1] → 101 (+21) [Q2]

13.1% more ownership

Funds ownership: 13.08% [Q1] → 26.18% (+13.1%) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for OCGN.

See Analyst Rankings

Financial journalist opinion

Based on 8 articles about OCGN published over the past 30 days

Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating Ocugen, Inc. (NASDAQ: OCGN) on behalf of the company's shareholders. Since July 2024, shares of Ocugen's stock have declined in value from a trading price of approximately $2.00 per share to a current trading price of less than $1.25 per share, a decline of over 37% in value. The investigation seeks to determine whether Ocugen and/or the company's officers and directors violated the securities laws or breached the.

Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm

Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3

Ocugen continues advancing its gene therapy pipeline, with OCU400 in Phase 3 trials for retinitis pigmentosa, targeting FDA approval by 2026. OCU400 has received the FDA's RMAT designation and is supported by an Expanded Access Program. Ocugen's broader pipeline includes OCU410 for geographic atrophy and OCU410ST for Stargardt disease, both progressing through early trials.

Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop

MALVERN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen, will speak during the workshop titled, “U.S.-India Biotechnology Cooperation: Realizing Benefits, Reducing Risks.” This two-day event will take place from September 9-11, 2024 in New Delhi, India.

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop

Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit

MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Arun Upadhyay, PhD, Ocugen's Chief Scientific Officer, Head of Research & Development, will be among the featured speakers at the 5 th Annual Gene Therapy for Ophthalmic Disorders conference, which is being held September 10-12, 2024 in Boston, Mass.

Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit

Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

MALVERN, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference taking place from September 9-11, 2024 in New York, NY.

Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

MALVERN, Pa., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the third cohort of its Phase 1/2 GARDian clinical trial for OCU410ST (AAV-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease. Stargardt disease affects approximately 100,000 people in the United States (U.S.) and Europe.

Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

Zacks Investment Research

Ocugen to Begin Phase III Study on Eye Drug in Canada, Stock Up

OCGN receives Health Canada's No Objection Letter to begin a phase III study on OCU400 for treating retinitis pigmentosa. Shares rise.

Ocugen to Begin Phase III Study on Eye Drug in Canada, Stock Up

Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

MALVERN, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Health Canada provided a “No Objection Letter” to initiate the OCU400 Phase 3 liMeliGhT (pronounced “limelight”) clinical trial in Canada. OCU400 is a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP).

Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

Ocugen, Inc. Investor Alert (NASDAQ: OCGN): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors Following Earnings Restatement and Possible Insider Trading

SAN FRANCISCO , Aug. 20, 2024 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Ocugen, Inc. investors that the firm is investigating potential legal claims relating to an earnings restatement and possible substantial insider trading by key executives and company directors. Current shareholders are encouraged to contact the firm regarding their rights.

Ocugen, Inc. Investor Alert (NASDAQ: OCGN): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors Following Earnings Restatement and Possible Insider Trading

Ocugen Provides Business Update with Second Quarter 2024 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ET Actively dosing patients in OCU400 Phase 3 liMeliGhT clinical trial OCU410 preliminary safety and efficacy data expected later this year Expanded access program approved for OCU400 $32.6 million net cash from underwritten public offering of common stock MALVERN, Pa.

Ocugen Provides Business Update with Second Quarter 2024 Financial Results

See News Rankings